Improved Persistence to Medication, Decreased Cardiovascular Events and Reduced All-Cause Mortality in Hypertensive Patients With Use of Single-Pill Combinations: Results From the START-Study

被引:26
|
作者
Schmieder, Roland E. [2 ]
Wassmann, Sven [3 ,4 ]
Predel, Hans-Georg [5 ]
Weisser, Burkhard [6 ]
Blettenberg, Joerg [7 ]
Gillessen, Anton [8 ]
Randerath, Olaf [1 ,9 ]
Mevius, Antje [10 ]
Wilke, Thomas [10 ]
Boehm, Michael [11 ]
机构
[1] APONTIS Pharm GmbH & Co KG, Alfred Nobel Str 10, D-40789 Monheim, Germany
[2] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Nephrol & Hypertens, Erlangen, Germany
[3] Fac Med, Cardiol Pasing, Munich, Germany
[4] Univ Saarland, Homburg Saar, Germany
[5] German Sport Univ Cologne, Inst Cardiol & Sports Med, Cologne, Germany
[6] Christian Albrechts Univ Kiel, Inst Sports Sci, Kiel, Germany
[7] Practice Dr J Blettenberg, Lindlar, Germany
[8] Herz Jesu Hosp, Dept Internal Med, Munster, Germany
[9] APONTIS Pharm Deutschland GmbH & Co, Med Dept, Monheim, Germany
[10] Inst Pharmakookon & Arzneimittellogist IPAM, Wismar, Germany
[11] Saarland Univ, Univ klinikum Saarlandes, Klin Innere Med 3, Homburg Saar, Germany
关键词
antihypertensive agents; cardiovascular diseases; hypertension; medication adherence; mortality; prognosis; risk factors; ANTIHYPERTENSIVE DRUG-TREATMENT; THERAPY CONTROVERSIES; ADHERENCE; RISK; METAANALYSIS; PREVALENCE; SOCIETY; IMPACT; SIDE;
D O I
10.1161/HYPERTENSIONAHA.122.20810
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
BACKGROUND: Single-pill combination improves adherence and persistence to medication in hypertension. It remains unclear whether this also reduces cardiovascular outcomes and all-cause mortality. We analyzed whether single-pill combinations are superior to identical multiple pills on persistence to medication, cardiovascular outcomes, and all-cause mortality. METHODS: This was a retrospective claims data (German AOK PLUS) analysis. Data from hypertensive patients >= 18 years treated with renin-angiotensin system combinations given as single pill or identical multipills covering the years 2012 to 2018 were analyzed and followed up to at least 1 year. After 1:1 propensity score matching, persistence to medication, cardiovascular events, and all-cause mortality were compared using non-parametric tests. Results were reported as incidence rate ratios and hazard ratios. RESULTS: After propensity score matching data from 57 998 patients were analyzed: 10 801 patients received valsartan/amlodipine, 1026 candesartan/amlodipine, 15 349 ramipril/amlodipine, and 1823 amlodipine/valsartan/hydrochlorothiazide as single pill or identical multipill. No relevant differences in patient characteristics were observed within the 4 groups. In all groups, a significant lower all-cause mortality, a significant a higher persistence to medication, a significant lower event rate in 15 out of 20 comparisons, and a tendency in the remaining 5 comparisons was observed under single pills compared with multipill combinations. CONCLUSIONS: Antihypertensive combination therapy reduces all-cause mortality and cardiovascular when provided as single pill compared to identical drugs as multipills. This strongly supports the European Society of Cardiology/European Society of Hypertension and International Society of Hypertension guidelines recommending the use of a single-pill combination and thus should be more rigorously implemented into daily clinical practice.
引用
收藏
页码:1127 / 1135
页数:9
相关论文
共 24 条
  • [21] Association of single measurement of estimated glomerular filtration rate and non-quantitative dipstick proteinuria with all-cause and cardiovascular mortality in the elderly. Results from the Progetto Veneto Anziani (Pro.V.A.) Study
    Zambon, Sabina
    Maggi, Stefania
    Zanoni, Silvia
    Romanato, Giovanna
    Noale, Marianna
    Corti, Maria Chiara
    Sartori, Leonardo
    Musacchio, Estella
    Baggio, Giovannella
    Sergi, Giuseppe
    Crepaldi, Gaetano
    Manzato, Enzo
    ATHEROSCLEROSIS, 2012, 220 (01) : 201 - 207
  • [22] Pre-Dialysis Neutrophil-Lymphocyte Ratio, a Novel and Strong Short-Term Predictor of All-Cause Mortality in Patients With Diabetic Nephropathy: Results From a Single-Center Study
    Sato, Hiroyuki
    Takeuchi, Yoichi
    Matsuda, Ken
    Kagaya, Saeko
    Saito, Ayako
    Fukami, Hirotaka
    Ojima, Yoshie
    Nagasawa, Tasuku
    THERAPEUTIC APHERESIS AND DIALYSIS, 2017, 21 (04) : 370 - 377
  • [23] High levels of high-density lipoprotein cholesterol (HDL-C) and major adverse cardiovascular events and 10-year all-cause mortality:results from Women's Ischemia Syndrome Evaluation (WISE) study
    Ranasinghe, S.
    Cui, Y.
    Obrutu, O.
    Wei, J.
    Gulati, M.
    Bittner, V.
    Reis, S.
    Handberg, E.
    Pepine, C.
    Merz, C. N. Bairey
    EUROPEAN HEART JOURNAL, 2023, 44
  • [24] Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study
    Langslet, Gisle
    Nystroem, Thomas
    Vistisen, Dorte
    Carstensen, Bendix
    Grip, Emilie Toresson
    Casajust, Paula
    Tskhvarashvili, Giorgi
    Hoti, Fabian
    Klement, Riho
    Karlsdotter, Kristina
    Tuovinen, Mikko
    Ofstad, Anne Pernille
    Lajer, Maria
    Shay, Christina
    Koeneman, Lisette
    Farsani, Soulmaz Fazeli
    Niskanen, Leo
    Halvorsen, Sigrun
    JOURNAL OF DIABETES RESEARCH, 2024, 2024